Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prapti Patel

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Blood Advances|February 15, 2019
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 studyGuillermo Garcia-Manero, Yasmin Abaza, Koichi Takahashi, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Blood|September 5, 2021
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AMLFei Yang, Nicola Long, Tauangtham Anekpuritanang, et al.
Transplantation and Cellular Therapy|November 14, 2021
Volumetric Modulated Arc Therapy Enabled Total Body Irradiation (VMAT-TBI): Six-year Clinical Experience and Treatment OutcomesElizabeth Ren Zhang-Velten, David Parsons, Pam Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Cancer Discovery|October 12, 2022
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired ResistanceJunhua Lyu, Yuxuan Liu, Lihu Gong, et al.
Blood Advances|July 17, 2023
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratoriesUma Borate, Fei Yang, Richard Press, et al.
Blood Advances|February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemiaAthalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
Nature Medicine|October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master TrialAmy Burd, Ross L Levine, Amy S Ruppert, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Blood Advances|February 15, 2019
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 studyGuillermo Garcia-Manero, Yasmin Abaza, Koichi Takahashi, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Blood|September 5, 2021
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AMLFei Yang, Nicola Long, Tauangtham Anekpuritanang, et al.
Transplantation and Cellular Therapy|November 14, 2021
Volumetric Modulated Arc Therapy Enabled Total Body Irradiation (VMAT-TBI): Six-year Clinical Experience and Treatment OutcomesElizabeth Ren Zhang-Velten, David Parsons, Pam Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Cancer Discovery|October 12, 2022
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired ResistanceJunhua Lyu, Yuxuan Liu, Lihu Gong, et al.
Blood Advances|July 17, 2023
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratoriesUma Borate, Fei Yang, Richard Press, et al.
Blood Advances|February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemiaAthalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
Nature Medicine|October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master TrialAmy Burd, Ross L Levine, Amy S Ruppert, et al.
Pageof 4